CleftGeneDB-Search

Gene: TYMS

Basic information

Tag	Content
Uniprot ID	P04818; Q8WYK3; Q8WYK4;
Entrez ID	7298
Genbank protein ID	BAB83677.1; AAH83512.1; BAB83676.1; AAH02567.1; CAA26178.1; BAA00472.1; EAX01720.1; BAA00404.1; EAX01716.1; AAH13919.1; BAB93473.1;
Genbank nucleotide ID	NM_001071.2
Ensembl protein ID	ENSP00000314727; ENSP00000315644; ENSP00000314902;
Ensembl nucleotide ID	ENSG00000176890
Gene name	Thymidylate synthase
Gene symbol	TYMS
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type	CPO,CL/P
Developmental stage
Data sources	Manually collected
Reference	23404871
Functional description	Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
Sequence	MPVAGSELPR RPLPPAAQER DAEPRPPHGE LQYLGQIQHI LRCGVRKDDR TGTGTLSVFG 60 MQARYSLRDE FPLLTTKRVF WKGVLEELLW FIKGSTNAKE LSSKGVKIWD ANGSRDFLDS 120 LGFSTREEGD LGPVYGFQWR HFGAEYRDME SDYSGQGVDQ LQRVIDTIKT NPDDRRIIMC 180 AWNPRDLPLM ALPPCHALCQ FYVVNSELSC QLYQRSGDMG LGVPFNIASY ALLTYMIAHI 240 TGLKPGDFIH TLGDAHIYLN HIEPLKIQLQ REPRPFPKLR ILRKVEKIDD FKAEDFQIEG 300 YNPHPTIKME MAV 313

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
1HVY
1HW3
1HW4
1HZW
1I00
1JU6
1JUJ
1YPV
2ONB
2RD8
2RDA
3EAW
3EBU
3ED7
3EDW
3EF9
3EGY
3EHI
3EJL
3GG5
3GH0
3GH2
3H9K
3HB8
3N5E
3N5G
3OB7
4E28
4FGT
4G2O
4G6W
4GD7
4GYH
4H1I
4JEF
4KPW
4O1U
4O1X
4UP1
5HS3
5WRN
5X4W
5X4X
5X4Y
5X5A
5X5D
5X5Q
5X66
5X67
5X69
6OJU
6OJV
6PF3
6PF4
6PF5
6PF6
6QXG
6QXH
6QYQ
6R2E
1HVY
1HZW
1YPV
3EBU
3ED7
3EHI
4E28

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Developmental stage	Species	Evidence	Details
1:1 ortholog	TYMS		F1MY63			Bos taurus	Prediction	More>>
1:1 ortholog	TYMS		A0A452DJS6			Capra hircus	Prediction	More>>
1:1 ortholog	TYMS	100060971	F6TRC0			Equus caballus	Prediction	More>>
1:1 ortholog	TYMS	7298	P04818	CPO,CL/P		Homo sapiens	Publication	More>>
1:1 ortholog	Tyms	22171	P07607		E14.5	Mus musculus	Prediction	More>>
1:1 ortholog	TYMS	740018	G2HEY4			Pan troglodytes	Prediction	More>>
1:1 ortholog	TYMS		A0A287AFN2			Sus scrofa	Prediction	More>>
1:1 ortholog	TYMS	100347408	G1SVL8			Oryctolagus cuniculus	Prediction	More>>
1:1 ortholog	Tyms	29261	P45352			Rattus norvegicus	Prediction	More>>
1:1 ortholog	tyms	81540	Q6P045			Danio rerio	Prediction	More>>

Identified variants/mutations related to cleft phenotype

Gene symbol	Significant Variants/SNPS	Methods	PubMed ID
TYMS	rs45445694; 28bp VNTR	Genotyping	23404871

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs1276365455	p.Pro2His	missense variant	-	NC_000018.10:g.657747C>A	gnomAD
rs910134246	p.Ala4Ser	missense variant	-	NC_000018.10:g.657752G>T	TOPMed,gnomAD
rs765119393	p.Gly5Ser	missense variant	-	NC_000018.10:g.657755G>A	ExAC,TOPMed,gnomAD
rs1257230944	p.Ser6Leu	missense variant	-	NC_000018.10:g.657759C>T	TOPMed,gnomAD
rs1257230944	p.Ser6Trp	missense variant	-	NC_000018.10:g.657759C>G	TOPMed,gnomAD
rs1337198820	p.Ser6Ala	missense variant	-	NC_000018.10:g.657758T>G	TOPMed,gnomAD
rs1190217127	p.Pro9Leu	missense variant	-	NC_000018.10:g.657768C>T	gnomAD
rs985633324	p.Arg10His	missense variant	-	NC_000018.10:g.657771G>A	TOPMed,gnomAD
rs985633324	p.Arg10Leu	missense variant	-	NC_000018.10:g.657771G>T	TOPMed,gnomAD
rs1475132959	p.Pro12Ala	missense variant	-	NC_000018.10:g.657776C>G	gnomAD
rs758379914	p.Leu13Ser	missense variant	-	NC_000018.10:g.657780T>C	ExAC,gnomAD
rs1172829435	p.Pro14Arg	missense variant	-	NC_000018.10:g.657783C>G	TOPMed,gnomAD
rs1172829435	p.Pro14His	missense variant	-	NC_000018.10:g.657783C>A	TOPMed,gnomAD
rs1172829435	p.Pro14Leu	missense variant	-	NC_000018.10:g.657783C>T	TOPMed,gnomAD
rs746824953	p.Pro15Arg	missense variant	-	NC_000018.10:g.657786C>G	ExAC,TOPMed,gnomAD
rs188268314	p.Pro15Ala	missense variant	-	NC_000018.10:g.657785C>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs188268314	p.Pro15Ser	missense variant	-	NC_000018.10:g.657785C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs746824953	p.Pro15His	missense variant	-	NC_000018.10:g.657786C>A	ExAC,TOPMed,gnomAD
rs1244183309	p.Gln18Arg	missense variant	-	NC_000018.10:g.657795A>G	TOPMed,gnomAD
rs1432304752	p.Gln18His	missense variant	-	NC_000018.10:g.657796G>T	gnomAD
rs914193673	p.Ala22Thr	missense variant	-	NC_000018.10:g.657806G>A	TOPMed
rs1365538416	p.Pro24Arg	missense variant	-	NC_000018.10:g.657813C>G	gnomAD
rs781495898	p.Pro24Ser	missense variant	-	NC_000018.10:g.657812C>T	ExAC,TOPMed,gnomAD
rs781495898	p.Pro24Thr	missense variant	-	NC_000018.10:g.657812C>A	ExAC,TOPMed,gnomAD
rs971608783	p.Arg25Leu	missense variant	-	NC_000018.10:g.657816G>T	gnomAD
rs971608783	p.Arg25His	missense variant	-	NC_000018.10:g.657816G>A	gnomAD
rs1280151022	p.Pro26Ser	missense variant	-	NC_000018.10:g.657818C>T	TOPMed,gnomAD
rs945359619	p.Pro27Leu	missense variant	-	NC_000018.10:g.657822C>T	TOPMed,gnomAD
rs1343318609	p.Pro27Ser	missense variant	-	NC_000018.10:g.657821C>T	gnomAD
rs556984495	p.His28Gln	missense variant	-	NC_000018.10:g.657826C>G	1000Genomes,ExAC,TOPMed,gnomAD
rs1275814898	p.Gly29Arg	missense variant	-	NC_000018.10:g.657827G>A	TOPMed
rs1034044510	p.Gln32Glu	missense variant	-	NC_000018.10:g.657836C>G	TOPMed,gnomAD
rs1186795888	p.Gly35Glu	missense variant	-	NC_000018.10:g.657846G>A	TOPMed,gnomAD
rs764376630	p.Gln36His	missense variant	-	NC_000018.10:g.657850G>T	TOPMed
rs764376630	p.Gln36His	missense variant	-	NC_000018.10:g.657850G>C	TOPMed
rs749802693	p.Arg42Leu	missense variant	-	NC_000018.10:g.657867G>T	ExAC
rs780327998	p.Arg42Cys	missense variant	-	NC_000018.10:g.657866C>T	ExAC,gnomAD
rs1376079761	p.Arg46Gly	missense variant	-	NC_000018.10:g.657878A>G	gnomAD
rs1339068086	p.Arg46Lys	missense variant	-	NC_000018.10:g.657879G>A	TOPMed
rs1470616694	p.Asp48Asn	missense variant	-	NC_000018.10:g.657884G>A	TOPMed
NCI-TCGA novel	p.Asp49Asn	missense variant	-	NC_000018.10:g.657887G>A	NCI-TCGA
rs774517504	p.Arg50Leu	missense variant	-	NC_000018.10:g.657891G>T	ExAC,TOPMed,gnomAD
rs762256027	p.Gly52Ser	missense variant	-	NC_000018.10:g.657896G>A	ExAC,TOPMed,gnomAD
rs1373657786	p.Thr53Ala	missense variant	-	NC_000018.10:g.657899A>G	TOPMed
rs1388727424	p.Gly54Ser	missense variant	-	NC_000018.10:g.657902G>A	gnomAD
rs1422282745	p.Leu56Pro	missense variant	-	NC_000018.10:g.657909T>C	TOPMed
rs1416155914	p.Ser57Trp	missense variant	-	NC_000018.10:g.657912C>G	gnomAD
rs1013467217	p.Met61Leu	missense variant	-	NC_000018.10:g.657923A>C	TOPMed
rs1332414425	p.Met61Ile	missense variant	-	NC_000018.10:g.657925G>A	gnomAD
rs1235927523	p.Gln62Arg	missense variant	-	NC_000018.10:g.657927A>G	gnomAD
rs1350646379	p.Ala63Val	missense variant	-	NC_000018.10:g.657930C>T	gnomAD
rs569127419	p.Ala63Thr	missense variant	-	NC_000018.10:g.657929G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs1270163632	p.Arg64His	missense variant	-	NC_000018.10:g.657933G>A	TOPMed,gnomAD
rs1270163632	p.Arg64Leu	missense variant	-	NC_000018.10:g.657933G>T	TOPMed,gnomAD
rs752269816	p.Ser66Arg	missense variant	-	NC_000018.10:g.657940C>A	ExAC,gnomAD
NCI-TCGA novel	p.Ser66Asn	missense variant	-	NC_000018.10:g.657939G>A	NCI-TCGA
NCI-TCGA novel	p.Asp69Gly	missense variant	-	NC_000018.10:g.659641A>G	NCI-TCGA
rs1386139292	p.Phe71Leu	missense variant	-	NC_000018.10:g.659648C>G	gnomAD
rs998190755	p.Pro72Leu	missense variant	-	NC_000018.10:g.659650C>T	TOPMed
rs1338576592	p.Arg78His	missense variant	-	NC_000018.10:g.659668G>A	TOPMed,gnomAD
rs139713318	p.Arg78Cys	missense variant	-	NC_000018.10:g.659667C>T	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Val79Glu	missense variant	-	NC_000018.10:g.659671T>A	NCI-TCGA
COSM4073039	p.Phe80Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.659673T>C	NCI-TCGA Cosmic
rs1449621034	p.Lys82Asn	missense variant	-	NC_000018.10:g.659681G>T	gnomAD
rs1182954109	p.Glu87Ala	missense variant	-	NC_000018.10:g.659695A>C	TOPMed
rs1459906556	p.Glu87Asp	missense variant	-	NC_000018.10:g.659696G>T	TOPMed
rs1258120815	p.Trp90Arg	missense variant	-	NC_000018.10:g.659703T>C	TOPMed
rs1200567277	p.Phe91Tyr	missense variant	-	NC_000018.10:g.659707T>A	TOPMed
rs1432195599	p.Ser95Cys	missense variant	-	NC_000018.10:g.662150C>G	gnomAD
rs59755869	p.Glu100Gln	missense variant	-	NC_000018.10:g.662164G>C	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Ser103Tyr	missense variant	-	NC_000018.10:g.662174C>A	NCI-TCGA
rs761906575	p.Val106Met	missense variant	-	NC_000018.10:g.662182G>A	ExAC,gnomAD
rs1198531715	p.Ala111Ser	missense variant	-	NC_000018.10:g.662197G>T	TOPMed
rs1255400378	p.Asp116Gly	missense variant	-	NC_000018.10:g.662213A>G	TOPMed
rs1464510968	p.Ser120Asn	missense variant	-	NC_000018.10:g.662225G>A	gnomAD
rs1250166783	p.Gly122Arg	missense variant	-	NC_000018.10:g.662230G>A	gnomAD
NCI-TCGA novel	p.Phe123Leu	missense variant	-	NC_000018.10:g.662235C>A	NCI-TCGA
NCI-TCGA novel	p.Ser124Phe	missense variant	-	NC_000018.10:g.662237C>T	NCI-TCGA
COSM3989612	p.Arg126Gly	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.662242A>G	NCI-TCGA Cosmic
rs1197981170	p.Arg126Lys	missense variant	-	NC_000018.10:g.662243G>A	gnomAD
NCI-TCGA novel	p.Glu127Ter	stop gained	-	NC_000018.10:g.662245G>T	NCI-TCGA
rs1057376810	p.Glu128Gly	missense variant	-	NC_000018.10:g.662249A>G	TOPMed
rs1386677048	p.Gly129Ala	missense variant	-	NC_000018.10:g.662252G>C	TOPMed,gnomAD
rs201415512	p.Val134Asp	missense variant	-	NC_000018.10:g.662267T>A	1000Genomes,ExAC,gnomAD
rs751072286	p.Gly136Ser	missense variant	-	NC_000018.10:g.662272G>A	ExAC,gnomAD
rs550446568	p.His141Tyr	missense variant	-	NC_000018.10:g.662287C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs1323389786	p.Phe142Leu	missense variant	-	NC_000018.10:g.662292T>G	gnomAD
rs1329714595	p.Gly143Glu	missense variant	-	NC_000018.10:g.662294G>A	gnomAD
rs780803284	p.Tyr146Ter	stop gained	-	NC_000018.10:g.662304C>G	ExAC,TOPMed,gnomAD
rs200442141	p.Arg147Lys	missense variant	-	NC_000018.10:g.662306G>A	1000Genomes,ExAC,gnomAD
rs756138720	p.Asp148Glu	missense variant	-	NC_000018.10:g.662310T>G	ExAC,TOPMed,gnomAD
rs1329031476	p.Asp148Ala	missense variant	-	NC_000018.10:g.662309A>C	gnomAD
rs1329031476	p.Asp148Gly	missense variant	-	NC_000018.10:g.662309A>G	gnomAD
rs940952547	p.Met149Ile	missense variant	-	NC_000018.10:g.662313G>A	TOPMed,gnomAD
rs1351759366	p.Met149Lys	missense variant	-	NC_000018.10:g.662312T>A	gnomAD
rs779644557	p.Met149Val	missense variant	-	NC_000018.10:g.662311A>G	ExAC,gnomAD
rs749119392	p.Glu150Gln	missense variant	-	NC_000018.10:g.662314G>C	ExAC,gnomAD
rs376793375	p.Glu150Asp	missense variant	-	NC_000018.10:g.662316A>T	ESP,ExAC,TOPMed,gnomAD
rs749119392	p.Glu150Lys	missense variant	-	NC_000018.10:g.662314G>A	ExAC,gnomAD
rs1025008996	p.Ser151Ala	missense variant	-	NC_000018.10:g.662317T>G	gnomAD
rs1255807993	p.Ser154Ala	missense variant	-	NC_000018.10:g.669077T>G	TOPMed
rs773099801	p.Gln162Arg	missense variant	-	NC_000018.10:g.669102A>G	ExAC,gnomAD
rs1300447329	p.Arg163Gly	missense variant	-	NC_000018.10:g.669104A>G	gnomAD
NCI-TCGA novel	p.Arg163SerPheSerTerUnk	frameshift	-	NC_000018.10:g.669102_669103AA>-	NCI-TCGA
rs747127849	p.Val164Ala	missense variant	-	NC_000018.10:g.669108T>C	ExAC,gnomAD
rs771296240	p.Ile165Thr	missense variant	-	NC_000018.10:g.669111T>C	ExAC,gnomAD
rs777163457	p.Asp166Tyr	missense variant	-	NC_000018.10:g.669113G>T	ExAC,gnomAD
rs1385336277	p.Lys169Glu	missense variant	-	NC_000018.10:g.669122A>G	TOPMed,gnomAD
rs147052596	p.Thr170Ser	missense variant	-	NC_000018.10:g.669126C>G	ESP,ExAC,TOPMed,gnomAD
rs1296735999	p.Asn171Lys	missense variant	-	NC_000018.10:g.669130C>G	TOPMed
rs770269195	p.Asp173Glu	missense variant	-	NC_000018.10:g.669136C>A	ExAC,TOPMed,gnomAD
rs776063973	p.Asp174Asn	missense variant	-	NC_000018.10:g.669137G>A	ExAC,gnomAD
COSM1564009	p.Arg176Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.669144G>A	NCI-TCGA Cosmic
rs761487013	p.Arg176Thr	missense variant	-	NC_000018.10:g.669144G>C	ExAC,TOPMed,gnomAD
rs761487013	p.Arg176Ile	missense variant	-	NC_000018.10:g.669144G>T	ExAC,TOPMed,gnomAD
rs767209304	p.Arg176Ser	missense variant	-	NC_000018.10:g.669145A>C	ExAC,TOPMed,gnomAD
rs1453521294	p.Ile177Thr	missense variant	-	NC_000018.10:g.669147T>C	TOPMed
rs1244429666	p.Ala181Thr	missense variant	-	NC_000018.10:g.669158G>A	TOPMed,gnomAD
rs760265884	p.Asn183Asp	missense variant	-	NC_000018.10:g.669164A>G	ExAC,gnomAD
rs753757524	p.Arg185Lys	missense variant	-	NC_000018.10:g.669171G>A	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Pro188His	missense variant	-	NC_000018.10:g.670698C>A	NCI-TCGA
rs1442205470	p.Met190Thr	missense variant	-	NC_000018.10:g.670704T>C	TOPMed
rs376500183	p.Ala191Val	missense variant	-	NC_000018.10:g.670707C>T	ESP,ExAC,TOPMed,gnomAD
rs1324146404	p.Cys195Ser	missense variant	-	NC_000018.10:g.670719G>C	gnomAD
NCI-TCGA novel	p.Cys195Ter	stop gained	-	NC_000018.10:g.670720C>A	NCI-TCGA
COSM1480441	p.Tyr202His	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.670739T>C	NCI-TCGA Cosmic
COSM417805	p.Glu207Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.670754G>A	NCI-TCGA Cosmic
rs1019504442	p.Gln211His	missense variant	-	NC_000018.10:g.670768G>C	TOPMed
rs373096647	p.Gln211Leu	missense variant	-	NC_000018.10:g.670767A>T	ESP,ExAC,TOPMed,gnomAD
rs201232749	p.Ser216Leu	missense variant	-	NC_000018.10:g.670782C>T	gnomAD
rs201232749	p.Ser216Trp	missense variant	-	NC_000018.10:g.670782C>G	gnomAD
NCI-TCGA novel	p.Asp218Glu	missense variant	-	NC_000018.10:g.670789C>G	NCI-TCGA
NCI-TCGA novel	p.Met219Arg	missense variant	-	NC_000018.10:g.670791T>G	NCI-TCGA
rs764943124	p.Leu221Phe	missense variant	-	NC_000018.10:g.670796C>T	gnomAD
rs1396826934	p.Gly222Ser	missense variant	-	NC_000018.10:g.670799G>A	TOPMed
rs1162827398	p.Ile227Val	missense variant	-	NC_000018.10:g.670814A>G	TOPMed
rs745957549	p.Ile227Met	missense variant	-	NC_000018.10:g.670816C>G	ExAC,gnomAD
NCI-TCGA novel	p.Ile227Asn	missense variant	-	NC_000018.10:g.670815T>A	NCI-TCGA
rs559346114	p.Ala228Ser	missense variant	-	NC_000018.10:g.670817G>T	1000Genomes,ExAC,TOPMed,gnomAD
rs559346114	p.Ala228Thr	missense variant	-	NC_000018.10:g.670817G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs772325743	p.Ser229Thr	missense variant	-	NC_000018.10:g.670821G>C	TOPMed
rs1369690699	p.Ser229Cys	missense variant	-	NC_000018.10:g.670820A>T	TOPMed
rs772325743	p.Ser229Asn	missense variant	-	NC_000018.10:g.670821G>A	TOPMed
NCI-TCGA novel	p.Ser229Arg	missense variant	-	NC_000018.10:g.670822C>G	NCI-TCGA
rs1304708715	p.Ala231Thr	missense variant	-	NC_000018.10:g.670826G>A	gnomAD
NCI-TCGA novel	p.Thr234Ala	missense variant	-	NC_000018.10:g.670835A>G	NCI-TCGA
rs1374898824	p.Tyr235Phe	missense variant	-	NC_000018.10:g.670839A>T	gnomAD
rs1267313145	p.Met236Leu	missense variant	-	NC_000018.10:g.670841A>C	TOPMed
rs1245548601	p.Met236Thr	missense variant	-	NC_000018.10:g.670842T>C	TOPMed
rs959180600	p.Ile237Met	missense variant	-	NC_000018.10:g.670846T>G	TOPMed
rs1223804477	p.Ile237Leu	missense variant	-	NC_000018.10:g.670844A>C	gnomAD
rs866542441	p.Ala238Val	missense variant	-	NC_000018.10:g.670848C>T	gnomAD
rs1220777084	p.Ile240Val	missense variant	-	NC_000018.10:g.670853A>G	gnomAD
rs750248338	p.Thr241Met	missense variant	-	NC_000018.10:g.670857C>T	TOPMed,gnomAD
NCI-TCGA novel	p.Gly242Ser	missense variant	-	NC_000018.10:g.670859G>A	NCI-TCGA
rs1448674651	p.Gly246Ala	missense variant	-	NC_000018.10:g.671384G>C	gnomAD
rs1448674651	p.Gly246Asp	missense variant	-	NC_000018.10:g.671384G>A	gnomAD
rs1350693342	p.Ile257Val	missense variant	-	NC_000018.10:g.671416A>G	TOPMed
rs761730468	p.Ile262Ser	missense variant	-	NC_000018.10:g.671432T>G	ExAC,gnomAD
rs143415597	p.Ile262Met	missense variant	-	NC_000018.10:g.671433C>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs780321607	p.Glu263Gln	missense variant	-	NC_000018.10:g.671434G>C	gnomAD
rs780321607	p.Glu263Lys	missense variant	-	NC_000018.10:g.671434G>A	gnomAD
rs1390986435	p.Leu265Arg	missense variant	-	NC_000018.10:g.671441T>G	TOPMed
rs1024764626	p.Arg271Gln	missense variant	-	NC_000018.10:g.672867G>A	TOPMed
NCI-TCGA novel	p.Pro277Ala	missense variant	-	NC_000018.10:g.672884C>G	NCI-TCGA
NCI-TCGA novel	p.Pro277Leu	missense variant	-	NC_000018.10:g.672885C>T	NCI-TCGA
rs970583280	p.Lys278Asn	missense variant	-	NC_000018.10:g.672889G>C	TOPMed
rs1467164009	p.Leu279Val	missense variant	-	NC_000018.10:g.672890C>G	TOPMed
rs751931801	p.Ile281Thr	missense variant	-	NC_000018.10:g.672897T>C	ExAC,gnomAD
NCI-TCGA novel	p.Arg283Ter	stop gained	-	NC_000018.10:g.672902C>T	NCI-TCGA
rs779604534	p.Val285Ile	missense variant	-	NC_000018.10:g.672908G>A	ExAC,gnomAD
NCI-TCGA novel	p.Val285Leu	missense variant	-	NC_000018.10:g.672908G>C	NCI-TCGA
rs369187265	p.Glu286Lys	missense variant	-	NC_000018.10:g.672911G>A	ESP,ExAC,gnomAD
NCI-TCGA novel	p.Glu286Gln	missense variant	-	NC_000018.10:g.672911G>C	NCI-TCGA
rs1328401362	p.Lys287Thr	missense variant	-	NC_000018.10:g.672915A>C	TOPMed
rs778541361	p.Ile288Thr	missense variant	-	NC_000018.10:g.672918T>C	ExAC,gnomAD
rs748095422	p.Asp289Gly	missense variant	-	NC_000018.10:g.672921A>G	ExAC,TOPMed,gnomAD
rs375413487	p.Ala293Thr	missense variant	-	NC_000018.10:g.672932G>A	ESP,ExAC,TOPMed,gnomAD
rs771147687	p.Ile298Thr	missense variant	-	NC_000018.10:g.672948T>C	ExAC,gnomAD
rs765591852	p.Glu299Lys	missense variant	-	NC_000018.10:g.672950G>A	TOPMed
rs776689763	p.Asn302Lys	missense variant	-	NC_000018.10:g.672961T>A	ExAC,gnomAD
rs759853185	p.Pro303Leu	missense variant	-	NC_000018.10:g.672963C>T	ExAC,TOPMed,gnomAD
rs1442195189	p.His304Tyr	missense variant	-	NC_000018.10:g.672965C>T	TOPMed
rs752774827	p.Pro305Arg	missense variant	-	NC_000018.10:g.672969C>G	ExAC,gnomAD
NCI-TCGA novel	p.Ile307Ser	missense variant	-	NC_000018.10:g.672975T>G	NCI-TCGA
rs763389486	p.Glu310Val	missense variant	-	NC_000018.10:g.672984A>T	ExAC,gnomAD
rs764603167	p.Met311Ile	missense variant	-	NC_000018.10:g.672988G>T	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Met311Leu	missense variant	-	NC_000018.10:g.672986A>T	NCI-TCGA
rs1289319018	p.Ala312Val	missense variant	-	NC_000018.10:g.672990C>T	gnomAD
rs751880836	p.Val313Ile	missense variant	-	NC_000018.10:g.672992G>A	ExAC,TOPMed,gnomAD

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0000786	Spontaneous abortion	phenotype	LHGDN
C0001339	Acute pancreatitis	disease	BEFREE
C0001418	Adenocarcinoma	group	BEFREE;LHGDN
C0001430	Adenoma	group	BEFREE
C0002170	Alopecia	disease	BEFREE
C0002871	Anemia	disease	BEFREE;CTD_human
C0002893	Refractory anemias	disease	BEFREE
C0003873	Rheumatoid Arthritis	disease	BEFREE;LHGDN
C0004114	Astrocytoma	disease	BEFREE
C0004763	Barrett Esophagus	disease	BEFREE
C0005684	Malignant neoplasm of urinary bladder	disease	BEFREE;RGD
C0005695	Bladder Neoplasm	group	BEFREE;RGD
C0006111	Brain Diseases	group	CTD_human
C0006118	Brain Neoplasms	group	BEFREE
C0006142	Malignant neoplasm of breast	disease	BEFREE;CTD_human
C0006826	Malignant Neoplasms	group	BEFREE
C0007102	Malignant tumor of colon	disease	BEFREE;CTD_human
C0007103	Malignant neoplasm of endometrium	disease	BEFREE
C0007107	Malignant neoplasm of larynx	disease	BEFREE
C0007113	Rectal Carcinoma	disease	BEFREE;CTD_human
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE
C0007134	Renal Cell Carcinoma	disease	BEFREE
C0007137	Squamous cell carcinoma	disease	BEFREE;CTD_human;LHGDN
C0007873	Uterine Cervical Neoplasm	disease	LHGDN
C0008924	Cleft upper lip	disease	BEFREE;CTD_human
C0008925	Cleft Palate	disease	BEFREE;CTD_human
C0009375	Colonic Neoplasms	group	BEFREE;CTD_human;LHGDN
C0009402	Colorectal Carcinoma	disease	BEFREE;CTD_human
C0009404	Colorectal Neoplasms	group	BEFREE;CTD_human;LHGDN
C0010346	Crohn Disease	disease	BEFREE
C0010606	Adenoid Cystic Carcinoma	disease	BEFREE
C0010823	Cytomegalovirus Infections	group	BEFREE;LHGDN
C0011991	Diarrhea	phenotype	BEFREE
C0012243	Digestive System Neoplasms	group	CTD_human
C0013080	Down Syndrome	disease	BEFREE
C0013221	Drug toxicity	group	CTD_human
C0014859	Esophageal Neoplasms	group	BEFREE;LHGDN
C0015672	Fatigue	phenotype	BEFREE
C0016412	Folic Acid Deficiency	disease	BEFREE
C0017168	Gastroesophageal reflux disease	disease	BEFREE
C0017636	Glioblastoma	disease	BEFREE;LHGDN
C0018133	Graft-vs-Host Disease	disease	BEFREE
C0018671	Head and Neck Neoplasms	group	CTD_human
C0018675	Head Neoplasms	group	CTD_human
C0018816	Heart Septal Defects	group	BEFREE
C0019156	Hepatic Veno-Occlusive Disease	disease	BEFREE
C0019348	Herpes Simplex Infections	group	BEFREE
C0021843	Intestinal Obstruction	disease	BEFREE
C0023418	leukemia	disease	BEFREE
C0023449	Acute lymphocytic leukemia	disease	BEFREE
C0023452	Childhood Acute Lymphoblastic Leukemia	disease	BEFREE
C0023467	Leukemia, Myelocytic, Acute	disease	BEFREE
C0023473	Myeloid Leukemia, Chronic	disease	BEFREE
C0023487	Acute Promyelocytic Leukemia	disease	BEFREE
C0023530	Leukopenia	disease	BEFREE
C0023787	Lipodystrophy	disease	BEFREE
C0023903	Liver neoplasms	group	BEFREE
C0024121	Lung Neoplasms	group	CTD_human;LHGDN
C0024232	Lymphatic Metastasis	disease	BEFREE
C0024299	Lymphoma	group	BEFREE;LHGDN
C0024301	Lymphoma, Follicular	disease	BEFREE;CTD_human
C0024302	Reticulosarcoma	disease	CTD_human
C0024304	Lymphoma, Mixed-Cell	disease	CTD_human
C0024305	Lymphoma, Non-Hodgkin	disease	BEFREE;CTD_human
C0024306	Lymphoma, Undifferentiated	disease	CTD_human
C0024530	Malaria	disease	BEFREE
C0024623	Malignant neoplasm of stomach	disease	BEFREE;CTD_human
C0024814	Marinesco-Sjogren syndrome	disease	BEFREE
C0025202	melanoma	disease	BEFREE
C0025286	Meningioma	disease	BEFREE;LHGDN
C0025322	Premature Menopause	phenotype	BEFREE
C0025500	Mesothelioma	disease	BEFREE
C0025517	Metabolic Diseases	group	BEFREE
C0026277	Mixed Salivary Gland Tumor	disease	BEFREE
C0026764	Multiple Myeloma	disease	BEFREE
C0026896	Myasthenia Gravis	disease	BEFREE
C0027533	Neck Neoplasms	group	CTD_human
C0027627	Neoplasm Metastasis	phenotype	BEFREE;LHGDN
C0027643	Neoplasm Recurrence, Local	phenotype	CTD_human
C0027651	Neoplasms	group	BEFREE
C0027765	nervous system disorder	group	CTD_human
C0027947	Neutropenia	disease	BEFREE
C0029463	Osteosarcoma	disease	BEFREE
C0029925	Ovarian Carcinoma	disease	BEFREE
C0030246	Pustulosis of Palms and Soles	disease	BEFREE
C0030297	Pancreatic Neoplasm	disease	CTD_human;LHGDN
C0030305	Pancreatitis	disease	BEFREE
C0031117	Peripheral Neuropathy	group	BEFREE
C0032285	Pneumonia	disease	BEFREE
C0032584	polyps	phenotype	BEFREE
C0033578	Prostatic Neoplasms	group	CTD_human;LHGDN
C0034885	Rectal Neoplasms	group	BEFREE;CTD_human
C0035335	Retinoblastoma	disease	BEFREE
C0035372	Rett Syndrome	disease	BEFREE
C0036220	Kaposi Sarcoma	disease	BEFREE
C0038356	Stomach Neoplasms	group	BEFREE;CTD_human;LHGDN
C0039483	Giant Cell Arteritis	disease	BEFREE
C0040034	Thrombocytopenia	phenotype	BEFREE
C0040411	Tongue Neoplasms	group	CTD_human
C0040517	Gilles de la Tourette syndrome	disease	BEFREE
C0040963	Tricuspid Valve Stenosis	disease	BEFREE
C0041341	Tuberous Sclerosis	disease	BEFREE
C0041755	Adverse reaction to drug	group	CTD_human
C0043346	Xeroderma Pigmentosum	disease	BEFREE
C0078981	Arachnoid Cysts	disease	BEFREE
C0079588	Ichthyosis, X-Linked	disease	BEFREE
C0079740	High Grade Lymphoma (neoplasm)	disease	CTD_human
C0079741	Lymphoma, Intermediate-Grade	disease	CTD_human
C0079744	Diffuse Large B-Cell Lymphoma	disease	BEFREE
C0079745	Lymphoma, Large-Cell, Follicular	disease	CTD_human
C0079747	Low Grade Lymphoma (neoplasm)	disease	CTD_human
C0079757	Diffuse Mixed-Cell Lymphoma	disease	CTD_human
C0079758	Lymphoma, Mixed-Cell, Follicular	disease	CTD_human
C0079765	Lymphoma, Small Cleaved-Cell, Follicular	disease	CTD_human
C0079770	Lymphoma, Small Noncleaved-Cell	disease	CTD_human
C0079772	T-Cell Lymphoma	disease	BEFREE
C0080178	Spina Bifida	disease	BEFREE
C0085215	Ovarian Failure, Premature	disease	BEFREE
C0085584	Encephalopathies	group	CTD_human
C0085669	Acute leukemia	disease	BEFREE
C0149782	Squamous cell carcinoma of lung	disease	BEFREE
C0149925	Small cell carcinoma of lung	disease	BEFREE
C0149931	Migraine Disorders	group	BEFREE
C0149978	Adenocarcinoma of rectum	disease	BEFREE
C0152013	Adenocarcinoma of lung (disorder)	disease	BEFREE;CTD_human
C0152018	Esophageal carcinoma	disease	BEFREE
C0153349	Malignant neoplasm of tongue	disease	CTD_human
C0153467	Malignant tumor of peritoneum	disease	BEFREE
C0153676	Secondary malignant neoplasm of lung	disease	BEFREE
C0175754	Agenesis of corpus callosum	disease	BEFREE
C0178874	Tumor Progression	phenotype	BEFREE
C0202236	Triglycerides measurement	phenotype	GWASDB
C0206623	Adenosquamous carcinoma	disease	BEFREE
C0206677	Adenomatous Polyps	disease	BEFREE
C0206686	Adrenocortical carcinoma	disease	BEFREE
C0206695	Carcinoma, Neuroendocrine	group	BEFREE;LHGDN
C0206754	Neuroendocrine Tumors	group	BEFREE;CTD_human;LHGDN
C0220994	Hyperammonemia	phenotype	CTD_human
C0235974	Pancreatic carcinoma	disease	BEFREE
C0238644	Anemia, severe	disease	BEFREE
C0242363	Islet Cell Tumor	disease	BEFREE
C0242379	Malignant neoplasm of lung	disease	BEFREE;CTD_human
C0242647	Mucosa-Associated Lymphoid Tissue Lymphoma	disease	BEFREE
C0262584	Carcinoma, Small Cell	disease	BEFREE
C0265325	Turcot syndrome (disorder)	disease	BEFREE
C0266836	Infantile Colic	phenotype	BEFREE
C0268138	Xeroderma Pigmentosum, Complementation Group D	disease	BEFREE
C0274576	Poisoning by fluorouracil	disease	ORPHANET
C0278480	Stage III Colon Cancer	disease	BEFREE
C0278484	Malignant neoplasm of colon stage IV	disease	BEFREE
C0278488	Carcinoma breast stage IV	disease	BEFREE
C0278498	Malignant neoplasm of stomach stage IV	disease	BEFREE
C0278678	Metastatic Renal Cell Cancer	disease	BEFREE
C0278701	Gastric Adenocarcinoma	disease	BEFREE
C0278987	Non-small cell lung cancer metastatic	disease	BEFREE
C0278996	Malignant Head and Neck Neoplasm	disease	BEFREE;CTD_human
C0279626	Squamous cell carcinoma of esophagus	disease	BEFREE
C0279628	Adenocarcinoma Of Esophagus	disease	BEFREE
C0279702	Conventional (Clear Cell) Renal Cell Carcinoma	disease	BEFREE
C0280100	Solid Neoplasm	phenotype	BEFREE
C0280242	stage, rectal cancer	phenotype	BEFREE
C0280803	Primary central nervous system lymphoma	disease	BEFREE
C0282160	Aplasia Cutis Congenita	disease	BEFREE
C0333997	Lymphoid hyperplasia	disease	BEFREE
C0338106	Adenocarcinoma of colon	disease	BEFREE
C0345967	Malignant mesothelioma	disease	BEFREE
C0346402	Malignant neoplasm of adrenal cortex	disease	BEFREE
C0346629	Malignant neoplasm of large intestine	disease	BEFREE
C0346647	Malignant neoplasm of pancreas	disease	BEFREE;CTD_human
C0349604	Intracranial Meningioma	disease	BEFREE
C0369183	Erythrocyte Mean Corpuscular Hemoglobin Test	phenotype	GWASCAT
C0376358	Malignant neoplasm of prostate	disease	BEFREE;CTD_human
C0376545	Hematologic Neoplasms	group	BEFREE
C0392885	High density lipoprotein measurement	phenotype	GWASDB
C0476089	Endometrial Carcinoma	disease	BEFREE
C0494165	Secondary malignant neoplasm of liver	disease	BEFREE
C0494463	Alzheimer Disease, Late Onset	disease	BEFREE
C0521158	Recurrent tumor	phenotype	BEFREE
C0521585	Gastrointestinal mucositis	disease	BEFREE
C0524587	Mean Corpuscular Volume (result)	phenotype	GWASCAT
C0546837	Malignant neoplasm of esophagus	disease	BEFREE
C0585442	Osteosarcoma of bone	disease	BEFREE
C0595989	Carcinoma of larynx	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0677886	Epithelial ovarian cancer	disease	BEFREE
C0677932	Progressive Neoplastic Disease	phenotype	BEFREE
C0677936	Refractory cancer	phenotype	BEFREE
C0677949	Stage III Colorectal Cancer	disease	BEFREE
C0677984	Locally Advanced Malignant Neoplasm	disease	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE;CTD_human
C0684249	Carcinoma of lung	disease	BEFREE
C0685938	Malignant neoplasm of gastrointestinal tract	disease	BEFREE
C0686619	Secondary malignant neoplasm of lymph node	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0699885	Carcinoma of bladder	disease	BEFREE
C0740394	Hyperuricemia	disease	BEFREE
C0740457	Malignant neoplasm of kidney	disease	BEFREE
C0746787	Cancer of Neck	disease	CTD_human
C0751075	Cancer of Digestive System	group	CTD_human
C0751177	Cancer of Head	disease	CTD_human
C0751606	Adult Acute Lymphocytic Leukemia	disease	BEFREE
C0812413	Malignant Pleural Mesothelioma	disease	BEFREE
C0853879	Invasive carcinoma of breast	disease	BEFREE
C0854750	Colorectal cancer recurrent	disease	BEFREE
C0854985	Adenocarcinoma of lung, stage I	disease	BEFREE
C0856825	Acute GVH disease	disease	BEFREE
C0887900	Upper Aerodigestive Tract Neoplasms	group	CTD_human
C0919267	ovarian neoplasm	disease	CTD_human;LHGDN
C0948168	Bone marrow toxicity	disease	BEFREE
C0948380	Colorectal cancer metastatic	disease	BEFREE
C1096458	Vascular occlusion	disease	BEFREE
C1112160	Gastrooesophageal cancer	disease	BEFREE
C1140680	Malignant neoplasm of ovary	disease	BEFREE;CTD_human
C1167725	Stage IV Pancreatic Cancer	disease	BEFREE
C1168401	Squamous cell carcinoma of the head and neck	disease	BEFREE
C1257931	Mammary Neoplasms, Human	group	CTD_human
C1261473	Sarcoma	group	BEFREE
C1261502	Finding of Mean Corpuscular Hemoglobin	phenotype	GWASCAT
C1302401	Adenoma of large intestine	disease	BEFREE
C1306459	Primary malignant neoplasm	group	BEFREE
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1319315	Adenocarcinoma of large intestine	disease	BEFREE;RGD
C1333762	Gastric Cardia Adenocarcinoma	disease	BEFREE
C1336076	Sporadic Breast Carcinoma	disease	BEFREE
C1367654	Marginal Zone B-Cell Lymphoma	disease	BEFREE
C1368683	Epithelioma	disease	BEFREE
C1378703	Renal carcinoma	disease	BEFREE
C1445957	Serum total cholesterol measurement	phenotype	GWASDB
C1458155	Mammary Neoplasms	group	BEFREE;CTD_human;LHGDN
C1527249	Colorectal Cancer	disease	BEFREE;CTD_human
C1559154	Rash and Dermatitis Adverse Event Associated with Chemoradiation	disease	BEFREE
C1621958	Glioblastoma Multiforme	disease	BEFREE
C1708349	Hereditary Diffuse Gastric Cancer	disease	CTD_human
C1832916	Timothy syndrome	disease	BEFREE
C1837218	Cleft palate, isolated	disease	CTD_human
C1883486	Uterine Corpus Cancer	disease	BEFREE
C1956130	Lymphoma, Follicular, Grade 1	disease	CTD_human
C1956131	Lymphoma, Follicular, Grade 3	disease	CTD_human
C1956132	Lymphoma, Follicular, Grade 2	disease	CTD_human
C1961102	Precursor Cell Lymphoblastic Leukemia Lymphoma	disease	BEFREE;LHGDN
C2239176	Liver carcinoma	disease	BEFREE;CTD_human;LHGDN
C2711227	Steatohepatitis	disease	BEFREE
C2717836	Steroid Sulfatase Deficiency Disease	disease	BEFREE
C2745948	Hyalinosis, Systemic	disease	BEFREE
C2931822	Nasopharyngeal carcinoma	disease	BEFREE
C2937421	Prostatic Hyperplasia	disease	LHGDN
C2939420	Metastatic Neoplasm	phenotype	BEFREE
C3146250	Stage III Colorectal Cancer AJCC v7	disease	BEFREE
C3146254	Stage III Colon Cancer AJCC v7	disease	BEFREE
C3539781	Progressive cGVHD	disease	BEFREE
C3642346	Luminal B Breast Carcinoma	disease	BEFREE
C3714542	Lymphoma, Diffuse	disease	CTD_human
C3714644	Thymus Neoplasms	group	BEFREE
C3887461	Head and Neck Carcinoma	disease	BEFREE

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0000166	nucleotide binding	IEA
GO:0000900	translation repressor activity, mRNA regulatory element binding	IDA
GO:0004799	thymidylate synthase activity	IDA
GO:0004799	thymidylate synthase activity	TAS
GO:0004799	thymidylate synthase activity	IBA
GO:0005542	folic acid binding	IC
GO:0042802	identical protein binding	IEA
GO:0048037	cofactor binding	IEA
GO:1990825	sequence-specific mRNA binding	IDA

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000083	regulation of transcription involved in G1/S transition of mitotic cell cycle	TAS
GO:0006231	dTMP biosynthetic process	IDA
GO:0006231	dTMP biosynthetic process	IBA
GO:0006235	dTTP biosynthetic process	IEA
GO:0007568	aging	IEA
GO:0007623	circadian rhythm	IEA
GO:0015949	nucleobase-containing small molecule interconversion	TAS
GO:0017148	negative regulation of translation	IDA
GO:0019088	immortalization of host cell by virus	IEA
GO:0019860	uracil metabolic process	IEA
GO:0032259	methylation	IEA
GO:0032570	response to progesterone	IEA
GO:0033189	response to vitamin A	IEA
GO:0034097	response to cytokine	IEA
GO:0035999	tetrahydrofolate interconversion	IDA
GO:0045471	response to ethanol	IEA
GO:0046078	dUMP metabolic process	IEA
GO:0046683	response to organophosphorus	IEP
GO:0048589	developmental growth	IEA
GO:0051216	cartilage development	IEA
GO:0051384	response to glucocorticoid	IEA
GO:0051593	response to folic acid	IEA
GO:0060574	intestinal epithelial cell maturation	IEA
GO:0071897	DNA biosynthetic process	IC
GO:0097421	liver regeneration	IEA

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005634	nucleus	IDA
GO:0005730	nucleolus	IEA
GO:0005737	cytoplasm	IDA
GO:0005739	mitochondrion	IBA
GO:0005739	mitochondrion	IDA
GO:0005743	mitochondrial inner membrane	IDA
GO:0005759	mitochondrial matrix	IDA
GO:0005829	cytosol	IBA
GO:0005829	cytosol	TAS

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-1430728	Metabolism	TAS
R-HSA-15869	Metabolism of nucleotides	TAS
R-HSA-1640170	Cell Cycle	TAS
R-HSA-453279	Mitotic G1 phase and G1/S transition	TAS
R-HSA-499943	Interconversion of nucleotide di- and triphosphates	TAS
R-HSA-69205	G1/S-Specific Transcription	TAS
R-HSA-69206	G1/S Transition	TAS
R-HSA-69278	Cell Cycle, Mitotic	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C495626	14-deoxy-11,12-didehydroandrographolide	14-deoxy-11,12-didehydroandrographolide results in decreased expression of TYMS mRNA	22101062
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in decreased expression of TYMS mRNA	24810058
D015058	1-Naphthylisothiocyanate	1-Naphthylisothiocyanate results in increased expression of TYMS mRNA	30723492
C029497	2,3-bis(3'-hydroxybenzyl)butyrolactone	2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of TYMS mRNA	19167446
C029497	2,3-bis(3'-hydroxybenzyl)butyrolactone	[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TYMS mRNA	19167446
C063002	2,3-dimethoxy-1,4-naphthoquinone	2,3-dimethoxy-1,4-naphthoquinone results in increased expression of TYMS mRNA	17547211; 19031421;
C016403	2,4-dinitrotoluene	2,4-dinitrotoluene affects the expression of TYMS mRNA	21346803
C023514	2,6-dinitrotoluene	2,6-dinitrotoluene affects the expression of TYMS mRNA	21346803
C007267	2'-deoxyuridylic acid	[Fluorouracil results in decreased activity of TYMS protein] which results in increased abundance of 2'-deoxyuridylic acid	29258758
C058706	2-desamino-2-methylaminopterin	2-desamino-2-methylaminopterin analog binds to and results in decreased activity of TYMS protein	1313737
C019499	2-nitrofluorene	2-nitrofluorene results in increased expression of TYMS mRNA	14600272; 15890375; 23052194;
C016392	3,3'-diindolylmethane	3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of TYMS mRNA]	11179685
C472791	3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid	3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid results in decreased expression of TYMS mRNA	16788091
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of TYMS mRNA	14600272; 15890375; 23052194;
C013123	5,10-methylenetetrahydrofolic acid	[Fluorodeoxyuridylate co-treated with 5,10-methylenetetrahydrofolic acid] binds to TYMS protein	15897250
C030371	5,6,7,8-tetrahydrofolic acid	5,6,7,8-tetrahydrofolic acid results in increased activity of TYMS protein	187325
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of TYMS mRNA	20382639
D015127	9,10-Dimethyl-1,2-benzanthracene	9,10-Dimethyl-1,2-benzanthracene results in increased expression of TYMS mRNA	22485181
C496492	abrine	abrine results in decreased expression of TYMS mRNA	31054353
D000082	Acetaminophen	Acetaminophen results in decreased expression of TYMS mRNA	21420995
D000082	Acetaminophen	Acetaminophen results in increased expression of TYMS mRNA	22230336
D000082	Acetaminophen	Acetaminophen affects the expression of TYMS mRNA	17562736
C063261	acetylleucyl-leucyl-norleucinal	acetylleucyl-leucyl-norleucinal inhibits the reaction [[Fluorouracil co-treated with Cisplatin] results in decreased stability of TYMS protein]	21444628
D016604	Aflatoxin B1	Aflatoxin B1 affects the expression of TYMS protein	20106945
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of TYMS mRNA	22100608; 27153756;
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of TYMS mRNA	14600272; 15890375; 23052194; 23630614; 25378103;
C412373	AG 1879	AG 1879 results in decreased expression of TYMS mRNA	18794807
C412373	AG 1879	AG 1879 results in decreased expression of TYMS protein	18794807
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of TYMS mRNA	16483693
D000952	Antigens, Polyomavirus Transforming	Antigens, Polyomavirus Transforming results in increased expression of TYMS mRNA	26680231
D000965	Antimony	Antimony results in increased expression of TYMS mRNA	17547211
D000966	Antimony Potassium Tartrate	Antimony Potassium Tartrate results in increased expression of TYMS mRNA	17547211
D018501	Antirheumatic Agents	TYMS gene polymorphism results in increased susceptibility to Antirheumatic Agents	18322994
D018501	Antirheumatic Agents	TYMS protein affects the susceptibility to Antirheumatic Agents	18322994
D000077237	Arsenic Trioxide	Arsenic Trioxide affects the activity of TYMS protein	25335113
D000077237	Arsenic Trioxide	Arsenic Trioxide affects the expression of TYMS mRNA	20501625
D000077237	Arsenic Trioxide	Arsenic Trioxide affects the expression of TYMS protein	25335113
D000077237	Arsenic Trioxide	[Arsenic Trioxide co-treated with Fluorouracil co-treated with Leucovorin] results in decreased expression of TYMS mRNA	20501625
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of TYMS mRNA	20530422; 22963400; 24691991; 25335113;
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of TYMS protein	20530422; 24691991;
D000077237	Arsenic Trioxide	Arsenic Trioxide results in increased expression of TYMS mRNA	17547211
D000077237	Arsenic Trioxide	TYMS protein results in decreased susceptibility to Arsenic Trioxide	24691991
C015001	arsenite	arsenite results in decreased expression of TYMS mRNA	18929588
D001280	Atrazine	Atrazine results in decreased expression of TYMS mRNA	22378314
D001379	Azathioprine	Azathioprine results in decreased expression of TYMS mRNA	22623647
D001397	Azoxymethane	[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TYMS mRNA	17893519
C487081	belinostat	belinostat results in decreased expression of TYMS mRNA	19606018
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of TYMS mRNA	20064835; 21802500;
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of TYMS mRNA	20106945
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of TYMS mRNA	22228805
C072553	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Fluorouracil co-treated with Cisplatin] results in decreased stability of TYMS protein]	21444628
C072553	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [trichostatin A results in decreased expression of TYMS protein]	17172411
C044887	beta-methylcholine	beta-methylcholine affects the expression of TYMS mRNA	21179406
D019324	beta-Naphthoflavone	[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TYMS mRNA	18164116
C002070	betulinic acid	betulinic acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of TYMS protein]	30136359
C002070	betulinic acid	betulinic acid promotes the reaction [Gefitinib results in decreased expression of TYMS protein]	30136359
C002070	betulinic acid	betulinic acid results in decreased expression of TYMS protein	30136359
C002070	betulinic acid	Erlotinib Hydrochloride promotes the reaction [betulinic acid results in decreased expression of TYMS protein]	30136359
C002070	betulinic acid	Gefitinib promotes the reaction [betulinic acid results in decreased expression of TYMS protein]	30136359
C504663	BGC638	BGC638 results in decreased activity of TYMS protein	16357184
C504662	BGC945	BGC945 results in decreased activity of TYMS protein	16357184
C504662	BGC945	BGC945 results in decreased activity of TYMS protein	21879757
C053541	bicalutamide	bicalutamide results in decreased expression of TYMS protein	17599054
C522781	biflorin	biflorin affects the expression of TYMS mRNA	27079618
C006780	bisphenol A	bisphenol A affects the expression of TYMS mRNA	30903817
C006780	bisphenol A	bisphenol A results in decreased expression of TYMS mRNA	29275510
C006780	bisphenol A	bisphenol A results in increased expression of TYMS mRNA	16474171
C006780	bisphenol A	bisphenol A results in increased expression of TYMS mRNA	29097150
D002087	Butyrates	Butyrates results in decreased expression of TYMS mRNA	20072153
D002104	Cadmium	Cadmium results in increased expression of TYMS mRNA	17547211
D002104	Cadmium	Cadmium results in increased expression of TYMS protein	14499349
D002104	Cadmium	Cadmium results in decreased expression of TYMS mRNA	24084258
D019256	Cadmium Chloride	Cadmium Chloride results in increased expression of TYMS mRNA	17547211
C037123	cadmium sulfate	[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of TYMS mRNA	18654764
D002110	Caffeine	Caffeine results in decreased expression of TYMS mRNA	20864626
D002117	Calcitriol	Calcitriol results in decreased expression of TYMS mRNA	21592394
D002117	Calcitriol	[Testosterone co-treated with Calcitriol] results in decreased expression of TYMS mRNA	21592394
D002166	Camptothecin	Camptothecin results in increased expression of TYMS mRNA	16568373
D000069287	Capecitabine	Capecitabine affects the expression of TYMS mRNA	16438929
D000069287	Capecitabine	[TYMS enhancer polymorphism co-treated with VEGFA gene SNP] affects the susceptibility to [Capecitabine co-treated with Oxaliplatin]	21048041
D000069287	Capecitabine	TYMS protein results in decreased susceptibility to Capecitabine	16734730
D002251	Carbon Tetrachloride	Carbon Tetrachloride affects the expression of TYMS mRNA	17484886
D016190	Carboplatin	PCNA mRNA affects the reaction [TYMS mRNA affects the susceptibility to Carboplatin]	16685392
C031662	CB 3717	CB 3717 analog results in decreased activity of TYMS protein	8632414
C031662	CB 3717	CB 3717 results in decreased activity of TYMS protein	3431591
D002509	Cephaloridine	Cephaloridine results in increased expression of TYMS mRNA	18500788
C095424	CF regimen	CF regimen results in decreased expression of TYMS mRNA	17638652
D002713	Chlorine	Chlorine results in decreased expression of TYMS mRNA	18636392
D002713	Chlorine	[Ozone co-treated with Chlorine] affects the expression of TYMS mRNA	18636392
D002857	Chromium	Chromium results in increased expression of TYMS mRNA	17547211
D002945	Cisplatin	acetylleucyl-leucyl-norleucinal inhibits the reaction [[Fluorouracil co-treated with Cisplatin] results in decreased stability of TYMS protein]	21444628
D002945	Cisplatin	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Fluorouracil co-treated with Cisplatin] results in decreased stability of TYMS protein]	21444628
D002945	Cisplatin	Cisplatin affects the expression of TYMS mRNA	23300844
D002945	Cisplatin	[Cisplatin co-treated with Fluorouracil] results in decreased expression of TYMS mRNA	15737843
D002945	Cisplatin	Cisplatin results in decreased degradation of TYMS protein	21444628
D002945	Cisplatin	Cisplatin results in increased activity of TYMS protein	16568373
D002945	Cisplatin	Cisplatin results in increased expression of TYMS mRNA	16568373; 21444628; 27392435;
D002945	Cisplatin	Cisplatin results in increased stability of TYMS mRNA	21444628
D002945	Cisplatin	[Fluorouracil co-treated with Cisplatin] results in decreased stability of TYMS protein	21444628
D002945	Cisplatin	PCNA mRNA affects the reaction [TYMS mRNA affects the susceptibility to Cisplatin]	16685392
D002945	Cisplatin	TYMS gene polymorphism results in decreased susceptibility to [Fluorouracil co-treated with Cisplatin]	16622263
D002945	Cisplatin	TYMS gene polymorphism results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Cisplatin co-treated with Paclitaxel]	16424979
D002945	Cisplatin	TYMS protein results in decreased susceptibility to Cisplatin	21444628
D002945	Cisplatin	U 0126 inhibits the reaction [Cisplatin results in decreased degradation of TYMS protein]	21444628
C018021	cobaltous chloride	[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of TYMS mRNA	18654764
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of TYMS mRNA	19320972
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of TYMS mRNA	24386269
D003300	Copper	[NSC 689534 binds to Copper] which results in decreased expression of TYMS mRNA	20971185
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of TYMS mRNA	19549813
D003375	Coumestrol	[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TYMS mRNA	19167446
D003375	Coumestrol	[Coumestrol co-treated with Resveratrol] results in increased expression of TYMS mRNA	19167446
D003375	Coumestrol	Coumestrol results in increased expression of TYMS mRNA	19167446
C408982	CPG-oligonucleotide	CPG-oligonucleotide results in decreased expression of TYMS mRNA	21878529
D003436	Croton Oil	Croton Oil results in increased expression of TYMS mRNA	21404309
D003513	Cycloheximide	Cycloheximide inhibits the reaction [trichostatin A results in decreased expression of TYMS mRNA]	17172411
D016572	Cyclosporine	Cyclosporine results in decreased expression of TYMS mRNA	20106945; 21632981; 25562108;
C093628	cyproconazole	cyproconazole affects the expression of TYMS mRNA	21621602
D003561	Cytarabine	TYMS gene polymorphism affects the susceptibility to Cytarabine	15713801
D003561	Cytarabine	Cytarabine results in increased activity of TYMS protein	15816533
D003630	Daunorubicin	TYMS gene polymorphism affects the susceptibility to Daunorubicin	15713801
D003634	DDT	DDT results in decreased expression of TYMS mRNA	25014179
D000077209	Decitabine	Decitabine affects the expression of TYMS mRNA	23300844
D016264	Dextran Sulfate	[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TYMS mRNA	17893519
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of TYMS mRNA	17361019; 21266533;
D004004	Dichlororibofuranosylbenzimidazole	Dichlororibofuranosylbenzimidazole inhibits the reaction [Fluorouracil results in increased expression of TYMS protein]	23056627
D004041	Dietary Fats	Dietary Fats results in increased expression of TYMS mRNA	25016146
D004052	Diethylnitrosamine	Diethylnitrosamine results in decreased expression of TYMS mRNA	12807726
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TYMS mRNA	18164116
D004054	Diethylstilbestrol	Diethylstilbestrol results in increased expression of TYMS mRNA	15890375
D004128	Dimethylnitrosamine	Dimethylnitrosamine results in increased expression of TYMS mRNA	14600272; 15890375;
D004137	Dinitrochlorobenzene	Dinitrochlorobenzene results in increased expression of TYMS mRNA	21404309
D000077143	Docetaxel	Docetaxel inhibits the reaction [Fluorouracil results in increased activity of TYMS protein]	16557585
D000077143	Docetaxel	Docetaxel inhibits the reaction [Fluorouracil results in increased expression of TYMS mRNA]	16557585
D000077143	Docetaxel	Docetaxel results in decreased expression of TYMS protein	16557585
D000077143	Docetaxel	Fluorouracil promotes the reaction [Docetaxel results in decreased expression of TYMS protein]	16557585
D000077143	Docetaxel	TYMS promoter polymorphism results in increased susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with Oxaliplatin co-treated with Docetaxel]	19074750
C025034	doxifluridine	doxifluridine affects the expression of TYMS mRNA	18630517
C025034	doxifluridine	[Paclitaxel co-treated with doxifluridine] affects the expression of TYMS mRNA	18630517
C025034	doxifluridine	TYMS protein results in decreased susceptibility to doxifluridine	16734730
D004317	Doxorubicin	[Doxorubicin co-treated with Paclitaxel] results in decreased expression of TYMS protein	16168113
D004317	Doxorubicin	Fluorouracil inhibits the reaction [[Doxorubicin co-treated with Paclitaxel] results in decreased expression of TYMS protein]	16168113
D013759	Dronabinol	Dronabinol results in decreased expression of TYMS mRNA	17934890
D004726	Endosulfan	Endosulfan results in decreased expression of TYMS mRNA	29391264
D004791	Enzyme Inhibitors	[Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of TYMS protein	23301498
D000069347	Erlotinib Hydrochloride	betulinic acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of TYMS protein]	30136359
D000069347	Erlotinib Hydrochloride	Erlotinib Hydrochloride promotes the reaction [betulinic acid results in decreased expression of TYMS protein]	30136359
D000069347	Erlotinib Hydrochloride	Erlotinib Hydrochloride results in decreased expression of TYMS protein	30136359
C472787	erucylphospho-N,N,N-trimethylpropylammonium	erucylphospho-N,N,N-trimethylpropylammonium results in decreased expression of TYMS mRNA	29464035
D004958	Estradiol	3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of TYMS mRNA]	11179685
D004958	Estradiol	Estradiol results in increased expression of TYMS mRNA	11179685; 16474171; 18310284; 19167446;
D004958	Estradiol	Tetrachlorodibenzodioxin inhibits the reaction [Estradiol results in increased expression of TYMS mRNA]	11179685
C034096	ethoxyacetic acid	ethoxyacetic acid affects the expression of TYMS mRNA	21621602
D005020	Ethyl Methanesulfonate	Ethyl Methanesulfonate results in increased expression of TYMS mRNA	23649840
D005047	Etoposide	TYMS gene polymorphism affects the susceptibility to Etoposide	15713801
C435305	FdUMP(10)	FdUMP(10) results in decreased activity of TYMS protein	15043163
D017313	Fenretinide	Fenretinide results in increased expression of TYMS mRNA	28973697
C082360	fipronil	fipronil results in increased expression of TYMS mRNA	23962444
D005467	Floxuridine	TYMS protein affects the susceptibility to Floxuridine	10482907
D005467	Floxuridine	TYMS protein results in decreased susceptibility to Floxuridine	15040806; 17018589;
D005467	Floxuridine	TYMS results in increased susceptibility to Floxuridine	2537495
D005467	Floxuridine	Floxuridine results in decreased activity of TYMS protein	15251465
D005468	Fluorodeoxyuridylate	[Fluorodeoxyuridylate co-treated with 5,10-methylenetetrahydrofolic acid] binds to TYMS protein	15897250
D005472	Fluorouracil	TYMS protein results in decreased susceptibility to Fluorouracil	18612238
D005472	Fluorouracil	Fluorouracil binds to TYMS protein	16619043
D005472	Fluorouracil	acetylleucyl-leucyl-norleucinal inhibits the reaction [[Fluorouracil co-treated with Cisplatin] results in decreased stability of TYMS protein]	21444628
D005472	Fluorouracil	[Arsenic Trioxide co-treated with Fluorouracil co-treated with Leucovorin] results in decreased expression of TYMS mRNA	20501625
D005472	Fluorouracil	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Fluorouracil co-treated with Cisplatin] results in decreased stability of TYMS protein]	21444628
D005472	Fluorouracil	[Cisplatin co-treated with Fluorouracil] results in decreased expression of TYMS mRNA	15737843
D005472	Fluorouracil	Dichlororibofuranosylbenzimidazole inhibits the reaction [Fluorouracil results in increased expression of TYMS protein]	23056627
D005472	Fluorouracil	Docetaxel inhibits the reaction [Fluorouracil results in increased activity of TYMS protein]	16557585
D005472	Fluorouracil	Docetaxel inhibits the reaction [Fluorouracil results in increased expression of TYMS mRNA]	16557585
D005472	Fluorouracil	Fluorouracil affects the expression of TYMS mRNA	18794807
D005472	Fluorouracil	Fluorouracil affects the expression of TYMS protein	18794807
D005472	Fluorouracil	[Fluorouracil co-treated with Cisplatin] results in decreased stability of TYMS protein	21444628
D005472	Fluorouracil	Fluorouracil inhibits the reaction [[Doxorubicin co-treated with Paclitaxel] results in decreased expression of TYMS protein]	16168113
D005472	Fluorouracil	Fluorouracil promotes the reaction [Docetaxel results in decreased expression of TYMS protein]	16557585
D005472	Fluorouracil	Fluorouracil promotes the reaction [geraniol results in decreased expression of TYMS mRNA]	15374632
D005472	Fluorouracil	Fluorouracil results in decreased activity of TYMS protein	12739060; 17339891;
D005472	Fluorouracil	Fluorouracil results in increased activity of TYMS protein	16557585
D005472	Fluorouracil	Fluorouracil results in increased expression of TYMS mRNA	15109396; 16557585; 16568373; 17330233; 18197934; 19084572; 19219653; 20570612; 21814787; 23056627; 8060136;
D005472	Fluorouracil	Fluorouracil results in increased expression of TYMS protein	15865071; 16168113; 16584549; 17172411; 23056627;
D005472	Fluorouracil	gambogic acid inhibits the reaction [Fluorouracil results in increased expression of TYMS mRNA]	19084572
D005472	Fluorouracil	[SU 9516 results in decreased expression of TYMS] which results in increased susceptibility to Fluorouracil	18425338
D005472	Fluorouracil	[TP53 affects the expression of TYMS] which affects the susceptibility to Fluorouracil	18600534
D005472	Fluorouracil	[trichostatin A results in decreased expression of TYMS protein] which results in increased susceptibility to Fluorouracil	17172411
D005472	Fluorouracil	TYMS 3' UTR mutant form results in decreased susceptibility to Fluorouracil	16267625
D005472	Fluorouracil	TYMS 3' UTR polymorphism affects the susceptibility to [Fluorouracil co-treated with Oxaliplatin]	15213713
D005472	Fluorouracil	TYMS 5' UTR polymorphism results in decreased susceptibility to Fluorouracil	16267625
D005472	Fluorouracil	TYMS affects the susceptibility to Fluorouracil	15067352
D005472	Fluorouracil	TYMS gene polymorphism affects the susceptibility to Fluorouracil	17016601; 18661526; 18722050; 19082493; 20714149;
D005472	Fluorouracil	TYMS gene polymorphism affects the susceptibility to [Fluorouracil co-treated with Oxaliplatin]	18448328
D005472	Fluorouracil	TYMS gene polymorphism results in decreased susceptibility to Fluorouracil	15446554
D005472	Fluorouracil	TYMS gene polymorphism results in decreased susceptibility to [Fluorouracil co-treated with Cisplatin]	16622263
D005472	Fluorouracil	TYMS gene polymorphism results in increased susceptibility to Fluorouracil	15735113; 18505590;
D005472	Fluorouracil	TYMS gene polymorphism results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Cisplatin co-treated with Paclitaxel]	16424979
D005472	Fluorouracil	TYMS mRNA affects the susceptibility to Fluorouracil	18507058; 18986760;
D005472	Fluorouracil	TYMS mRNA affects the susceptibility to [Irinotecan co-treated with Fluorouracil co-treated with Leucovorin]	17454858
D005472	Fluorouracil	TYMS mRNA results in decreased susceptibility to Fluorouracil	15246190; 18383874; 18490900; 18593893;
D005472	Fluorouracil	TYMS mRNA results in increased susceptibility to Fluorouracil	15239142
D005472	Fluorouracil	TYMS promoter polymorphism affects the susceptibility to Fluorouracil	16596248
D005472	Fluorouracil	TYMS promoter polymorphism results in increased susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with Oxaliplatin co-treated with Docetaxel]	19074750
D005472	Fluorouracil	TYMS protein affects the susceptibility to Fluorouracil	10482907; 15538739; 15548681; 15655543; 15735113; 15788669; 16160472; 17203168; 17339891; 17609664; 18197934; 18505590; 18607850; 18633250; 18794807; 19020767;
D005472	Fluorouracil	TYMS protein affects the susceptibility to Fluorouracil analog	15608557
D005472	Fluorouracil	TYMS protein affects the susceptibility to [Fluorouracil co-treated with Leucovorin]	18676755
D005472	Fluorouracil	TYMS protein results in decreased susceptibility to Fluorouracil	14970324; 15890242; 15918040; 15993511; 16282729; 17018589; 17047489; 17172411; 17377791; 17520254; 18490900; 19105824;
D005472	Fluorouracil	TYMS protein results in increased susceptibility to Fluorouracil	15446554; 15770397; 16267625;
D005472	Fluorouracil	TYMS results in decreased susceptibility to Fluorouracil	7763285
D005472	Fluorouracil	TYMS results in increased susceptibility to Fluorouracil	2537495
D005472	Fluorouracil	[wogonin co-treated with Fluorouracil] results in increased expression of TYMS mRNA	20570612
D005472	Fluorouracil	Fluorouracil results in decreased activity of TYMS protein	29258758; 9299594;
D005472	Fluorouracil	[Fluorouracil results in decreased activity of TYMS protein] which results in decreased abundance of Thymidine Monophosphate	29258758
D005472	Fluorouracil	[Fluorouracil results in decreased activity of TYMS protein] which results in increased abundance of 2'-deoxyuridylic acid	29258758
D005472	Fluorouracil	Fluorouracil results in decreased expression of TYMS	9050858
D005472	Fluorouracil	Leucovorin promotes the reaction [Fluorouracil results in decreased expression of TYMS]	9050858
D005472	Fluorouracil	Thymidine inhibits the reaction [Fluorouracil results in decreased expression of TYMS]	9050858
D005472	Fluorouracil	Fluorouracil results in decreased activity of TYMS protein	9299594
D005472	Fluorouracil	Fluorouracil results in decreased activity of TYMS	19147506; 19816940;
D005472	Fluorouracil	TYMS protein affects the metabolism of Fluorouracil	16012767
D005472	Fluorouracil	TYMS results in decreased susceptibility to Fluorouracil	19023200
D005480	Flurbiprofen	Flurbiprofen results in increased expression of TYMS mRNA	16949054
C061365	flusilazole	flusilazole affects the expression of TYMS mRNA	21621602
C410216	Folfox protocol	TYMS gene polymorphism results in increased susceptibility to Folfox protocol analog	18505590
D005492	Folic Acid	Folic Acid affects the expression of TYMS mRNA	17311948; 17320366;
D005492	Folic Acid	Folic Acid analog results in decreased activity of TYMS protein	2909728
D005492	Folic Acid	Folic Acid deficiency results in increased expression of TYMS mRNA	18623116
D005492	Folic Acid	Folic Acid results in increased expression of TYMS protein	187325
C074694	FuMi protocol	TYMS gene polymorphism affects the susceptibility to FuMi protocol	18498133
C039281	furan	furan results in increased expression of TYMS mRNA	25539665; 26194646;
C052659	gambogic acid	gambogic acid inhibits the reaction [Fluorouracil results in increased expression of TYMS mRNA]	19084572
C052659	gambogic acid	gambogic acid results in decreased expression of TYMS mRNA	19084572
D000077156	Gefitinib	betulinic acid promotes the reaction [Gefitinib results in decreased expression of TYMS protein]	30136359
D000077156	Gefitinib	Gefitinib promotes the reaction [betulinic acid results in decreased expression of TYMS protein]	30136359
D000077156	Gefitinib	Gefitinib results in decreased expression of TYMS mRNA	18347146
D000077156	Gefitinib	Gefitinib results in decreased expression of TYMS protein	18347146; 30136359;
D000077156	Gefitinib	TYMS protein affects the susceptibility to [Gefitinib co-treated with S 1 (combination)]	18347146
D019833	Genistein	Genistein results in increased expression of TYMS mRNA	16474171
D005839	Gentamicins	Gentamicins results in decreased expression of TYMS mRNA	22061828
C007836	geraniol	Fluorouracil promotes the reaction [geraniol results in decreased expression of TYMS mRNA]	15374632
C007836	geraniol	geraniol results in decreased expression of TYMS mRNA	15374632
C000593030	GSK-J4	GSK-J4 results in decreased expression of TYMS mRNA	29301935
D007065	Idoxuridine	TYMS protein affects the uptake of Idoxuridine	15001691
C545476	incobotulinumtoxinA	incobotulinumtoxinA results in decreased expression of TYMS mRNA	29522793
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TYMS mRNA	25613284
D000077146	Irinotecan	TYMS mRNA affects the susceptibility to [Irinotecan co-treated with Fluorouracil co-treated with Leucovorin]	17454858
C561695	(+)-JQ1 compound	(+)-JQ1 compound analog binds to TYMS protein	24972113
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of TYMS mRNA	23086925; 24796395; 25961927;
C410337	K 7174	K 7174 results in decreased expression of TYMS mRNA	24086573
D007649	Ketamine	Ketamine results in decreased expression of TYMS mRNA	20080153
D019259	Lamivudine	[Zidovudine co-treated with Lamivudine] results in decreased expression of TYMS mRNA	15784690
D007840	Latex	Latex analog results in increased expression of TYMS mRNA	24768652
C029891	lead chloride	[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of TYMS mRNA	18654764
D002955	Leucovorin	[Arsenic Trioxide co-treated with Fluorouracil co-treated with Leucovorin] results in decreased expression of TYMS mRNA	20501625
D002955	Leucovorin	TYMS gene polymorphism results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Cisplatin co-treated with Paclitaxel]	16424979
D002955	Leucovorin	TYMS mRNA affects the susceptibility to [Irinotecan co-treated with Fluorouracil co-treated with Leucovorin]	17454858
D002955	Leucovorin	TYMS promoter polymorphism results in increased susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with Oxaliplatin co-treated with Docetaxel]	19074750
D002955	Leucovorin	TYMS protein affects the susceptibility to [Fluorouracil co-treated with Leucovorin]	18676755
D002955	Leucovorin	Leucovorin promotes the reaction [Fluorouracil results in decreased expression of TYMS]	9050858
D008070	Lipopolysaccharides	Lipopolysaccharides affects the expression of TYMS mRNA	28070326
D008070	Lipopolysaccharides	Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of TYMS mRNA]	28070326
D008294	Malathion	Malathion results in decreased expression of TYMS mRNA	16079077
D015122	Mercaptopurine	TYMS gene polymorphism affects the susceptibility to Mercaptopurine	15713801
D008628	Mercury	Mercury results in increased expression of TYMS mRNA	17547211
D008701	Methapyrilene	Methapyrilene results in increased expression of TYMS mRNA	15890375
D008727	Methotrexate	Methotrexate results in decreased expression of TYMS mRNA	23897011
D008727	Methotrexate	Methotrexate results in increased expression of TYMS mRNA	23838799
D008727	Methotrexate	Methotrexate results in increased expression of TYMS protein	22484375
D008727	Methotrexate	TYMS 3' UTR polymorphism affects the susceptibility to Methotrexate	17410198
D008727	Methotrexate	TYMS 5' UTR polymorphism affects the susceptibility to Methotrexate	17410198
D008727	Methotrexate	TYMS 5' UTR polymorphism results in decreased susceptibility to Methotrexate	16267625
D008727	Methotrexate	TYMS gene polymorphism affects the susceptibility to Methotrexate	15713801; 25007187;
D008727	Methotrexate	TYMS protein results in increased susceptibility to Methotrexate	16267625
D008727	Methotrexate	TYMS results in increased susceptibility to Methotrexate	2537495
D008727	Methotrexate	Methotrexate results in increased expression of TYMS protein	187325
C013598	methoxyacetic acid	methoxyacetic acid affects the expression of TYMS mRNA	21621602
C013598	methoxyacetic acid	methoxyacetic acid results in decreased expression of TYMS mRNA	20864626
D008748	Methylcholanthrene	Methylcholanthrene results in increased expression of TYMS mRNA	22100608
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of TYMS mRNA	20864626
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in decreased expression of TYMS mRNA	26011545
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in increased expression of TYMS mRNA	22100608; 23649840;
C008493	methylselenic acid	methylselenic acid affects the expression of TYMS mRNA	14617803
C008493	methylselenic acid	methylselenic acid results in decreased expression of TYMS mRNA	12517777
D008777	Methyltestosterone	Methyltestosterone results in increased expression of TYMS mRNA	29458080
D016685	Mitomycin	Mitomycin results in increased expression of TYMS mRNA	16568373
C028577	monobutyl phthalate	monobutyl phthalate results in decreased expression of TYMS mRNA	20864626
C047806	monomethylpropion	monomethylpropion results in increased expression of TYMS mRNA	22303338
D009532	Nickel	Nickel results in increased expression of TYMS mRNA	25583101
C022838	nickel chloride	nickel chloride affects the expression of TYMS mRNA	22110744
C014707	nitrosobenzylmethylamine	nitrosobenzylmethylamine results in increased expression of TYMS mRNA	17616710
C002741	N-nitrosomorpholine	N-nitrosomorpholine results in increased expression of TYMS mRNA	19716841
C044387	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of TYMS mRNA	12888634
C099178	nolatrexed	nolatrexed results in decreased activity of TYMS protein	17339891
C099178	nolatrexed	TYMS protein affects the susceptibility to nolatrexed	17339891
C558013	NSC 689534	[NSC 689534 binds to Copper] which results in decreased expression of TYMS mRNA	20971185
C466913	NU2058	NU2058 results in decreased expression of TYMS protein	17599054
D000077150	Oxaliplatin	Oxaliplatin results in decreased expression of TYMS mRNA	15057142
D000077150	Oxaliplatin	Oxaliplatin results in decreased expression of TYMS protein	15057142
D000077150	Oxaliplatin	TYMS 3' UTR polymorphism affects the susceptibility to [Fluorouracil co-treated with Oxaliplatin]	15213713
D000077150	Oxaliplatin	[TYMS enhancer polymorphism co-treated with VEGFA gene SNP] affects the susceptibility to [Capecitabine co-treated with Oxaliplatin]	21048041
D000077150	Oxaliplatin	TYMS gene polymorphism affects the susceptibility to [Fluorouracil co-treated with Oxaliplatin]	18448328
D000077150	Oxaliplatin	TYMS promoter polymorphism results in increased susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with Oxaliplatin co-treated with Docetaxel]	19074750
D000077150	Oxaliplatin	[Oxaliplatin co-treated with Topotecan] results in decreased expression of TYMS mRNA	25729387
D000077150	Oxaliplatin	Oxaliplatin results in decreased expression of TYMS mRNA	25729387
C100692	oxamflatin	oxamflatin results in decreased expression of TYMS protein	17172411
D010081	Oxazolone	Oxazolone results in increased expression of TYMS mRNA	21404309
D010100	Oxygen	Oxygen deficiency results in decreased expression of TYMS mRNA	24205000
D010126	Ozone	[NOTCH3 gene mutant form affects the susceptibility to Ozone] which results in increased expression of TYMS mRNA	25658374
D010126	Ozone	[Ozone co-treated with Chlorine] affects the expression of TYMS mRNA	18636392
D017239	Paclitaxel	[Doxorubicin co-treated with Paclitaxel] results in decreased expression of TYMS protein	16168113
D017239	Paclitaxel	Fluorouracil inhibits the reaction [[Doxorubicin co-treated with Paclitaxel] results in decreased expression of TYMS protein]	16168113
D017239	Paclitaxel	Paclitaxel affects the expression of TYMS mRNA	18630517
D017239	Paclitaxel	[Paclitaxel co-treated with doxifluridine] affects the expression of TYMS mRNA	18630517
D017239	Paclitaxel	Paclitaxel results in increased expression of TYMS mRNA	16568373
D017239	Paclitaxel	TYMS gene polymorphism results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Cisplatin co-treated with Paclitaxel]	16424979
C500026	palbociclib	palbociclib results in decreased expression of TYMS mRNA	22869556
C500026	palbociclib	palbociclib results in decreased expression of TYMS protein	20948315
D000068437	Pemetrexed	Pemetrexed results in decreased activity of TYMS protein	17339891
D000068437	Pemetrexed	TYMS affects the susceptibility to Pemetrexed	21742432
D000068437	Pemetrexed	TYMS protein affects the susceptibility to Pemetrexed	17339891
D000068437	Pemetrexed	TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein]	15161716
D000068437	Pemetrexed	Pemetrexed results in decreased activity of TYMS protein	17465208
D010634	Phenobarbital	Phenobarbital affects the expression of TYMS mRNA	19159669
D010634	Phenobarbital	Phenobarbital affects the expression of TYMS mRNA	23091169
D020113	Phenolphthalein	Phenolphthalein results in decreased activity of TYMS protein	21696158
C415326	phenoxyacetic acid	phenoxyacetic acid affects the expression of TYMS mRNA	21621602
D048789	Phytoestrogens	Phytoestrogens results in increased expression of TYMS mRNA	18310284
D010882	Piperonyl Butoxide	Piperonyl Butoxide results in increased expression of TYMS mRNA	15890375
C006253	pirinixic acid	pirinixic acid results in increased expression of TYMS mRNA	23811191
C006253	pirinixic acid	pirinixic acid results in increased expression of TYMS mRNA	15890375; 19162173;
D010936	Plant Extracts	Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of TYMS mRNA]	28070326
D010936	Plant Extracts	Plant Extracts results in decreased expression of TYMS mRNA	23557933
D011078	Polychlorinated Biphenyls	Polychlorinated Biphenyls analog results in increased expression of TYMS mRNA	16474171
D011192	Potassium Dichromate	Potassium Dichromate results in increased expression of TYMS mRNA	17547211
D011241	Prednisone	TYMS gene polymorphism affects the susceptibility to Prednisone	15713801
D011374	Progesterone	Progesterone results in decreased expression of TYMS mRNA	21795739
D011374	Progesterone	Progesterone results in increased expression of TYMS mRNA	18070364
D011624	Pteroylpolyglutamic Acids	Pteroylpolyglutamic Acids analog results in decreased activity of TYMS protein	2909728
D011794	Quercetin	Quercetin results in decreased expression of TYMS protein	16573383
D011794	Quercetin	Quercetin results in increased expression of TYMS mRNA	21632981
D011794	Quercetin	Quercetin results in decreased expression of TYMS mRNA	17103110
D011799	Quinazolines	Quinazolines analog results in decreased activity of TYMS protein	2909728
C068874	raltitrexed	raltitrexed results in decreased activity of TYMS protein	17339891
C068874	raltitrexed	TYMS protein affects the susceptibility to raltitrexed	10482907; 17339891;
C068874	raltitrexed	TYMS protein inhibits the reaction [raltitrexed results in increased expression of ANXA2 mRNA]	15152939
C068874	raltitrexed	TYMS protein inhibits the reaction [raltitrexed results in increased expression of FAS protein]	15161716
C068874	raltitrexed	TYMS protein inhibits the reaction [raltitrexed results in increased expression of SAT1 mRNA]	15152939
D000077185	Resveratrol	[Coumestrol co-treated with Resveratrol] results in increased expression of TYMS mRNA	19167446
D000077185	Resveratrol	Resveratrol results in increased expression of TYMS mRNA	19167446
D012402	Rotenone	Rotenone results in decreased expression of TYMS mRNA	24810058; 29955902;
C079198	S 1 (combination)	TYMS protein affects the susceptibility to [Gefitinib co-treated with S 1 (combination)]	18347146
D012822	Silicon Dioxide	Silicon Dioxide results in decreased expression of TYMS mRNA	19073995
D019821	Simvastatin	Simvastatin results in decreased expression of TYMS mRNA	17428261
D019821	Simvastatin	Simvastatin results in decreased expression of TYMS protein	17428261
D020123	Sirolimus	Sirolimus results in decreased expression of TYMS	20682991
D020123	Sirolimus	Sirolimus results in decreased expression of TYMS mRNA	19764996
C017947	sodium arsenite	sodium arsenite results in increased expression of TYMS mRNA	29361514
C017947	sodium arsenite	sodium arsenite results in increased expression of TYMS mRNA	29301061
C016104	sodium bichromate	sodium bichromate affects the expression of TYMS mRNA	22110744
C016104	sodium bichromate	sodium bichromate results in increased expression of TYMS mRNA	25993096
D053260	Soot	Soot results in increased expression of TYMS mRNA	22461453
C030000	stallimycin	stallimycin analog results in decreased expression of and results in decreased activity of TYMS protein	21814787
C030000	stallimycin	stallimycin results in decreased expression of TYMS mRNA	21814787
C030000	stallimycin	stallimycin binds to TYMS mRNA	21814787
C433985	SU 9516	SU 9516 results in decreased expression of TYMS	18425338
C433985	SU 9516	[SU 9516 results in decreased expression of TYMS] which results in increased susceptibility to Fluorouracil	18425338
D000077210	Sunitinib	Sunitinib results in decreased expression of TYMS mRNA	31533062
C112689	TAC 101	TAC 101 results in decreased expression of TYMS protein	10225456
C112765	tanespimycin	tanespimycin results in decreased expression of TYMS protein	18830594
D005641	Tegafur	TYMS promoter polymorphism affects the susceptibility to Tegafur	16617381
C401859	temsirolimus	temsirolimus results in decreased expression of TYMS mRNA	19764996
D013739	Testosterone	[Testosterone co-treated with Calcitriol] results in decreased expression of TYMS mRNA	21592394
D013739	Testosterone	Testosterone results in decreased expression of TYMS mRNA	21592394
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin inhibits the reaction [Estradiol results in increased expression of TYMS mRNA]	11179685
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of TYMS mRNA	21802500
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of TYMS mRNA	19684285
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of TYMS mRNA	21570461
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of TYMS mRNA	15667827
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of TYMS mRNA	22298810
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate results in increased expression of TYMS mRNA	19031421
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TYMS mRNA	25613284
D019284	Thapsigargin	Thapsigargin results in decreased expression of TYMS mRNA	22378314
D013853	Thioacetamide	Thioacetamide results in increased expression of TYMS mRNA	23411599
D013936	Thymidine	Thymidine inhibits the reaction [Fluorouracil results in decreased expression of TYMS]	9050858
D013938	Thymidine Monophosphate	[Fluorouracil results in decreased activity of TYMS protein] which results in decreased abundance of Thymidine Monophosphate	29258758
C009495	titanium dioxide	[Vitallium analog binds to titanium dioxide] which results in decreased expression of TYMS mRNA	23825117
C009495	titanium dioxide	titanium dioxide results in increased expression of TYMS mRNA	23557971; 27760801;
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in decreased expression of TYMS mRNA	28065790
D014051	Toluene 2,4-Diisocyanate	Toluene 2,4-Diisocyanate results in increased expression of TYMS mRNA	21404309
D019772	Topotecan	[Oxaliplatin co-treated with Topotecan] results in decreased expression of TYMS mRNA	25729387
D019772	Topotecan	Topotecan results in decreased expression of TYMS mRNA	25729387
D014212	Tretinoin	Tretinoin results in decreased expression of TYMS mRNA	16249480; 21934132;
C012589	trichostatin A	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [trichostatin A results in decreased expression of TYMS protein]	17172411
C012589	trichostatin A	Cycloheximide inhibits the reaction [trichostatin A results in decreased expression of TYMS mRNA]	17172411
C012589	trichostatin A	trichostatin A results in decreased expression of TYMS mRNA	17172411; 19606018;
C012589	trichostatin A	trichostatin A results in decreased expression of TYMS protein	17172411
C012589	trichostatin A	[trichostatin A results in decreased expression of TYMS protein] which results in increased susceptibility to Fluorouracil	17172411
C012589	trichostatin A	trichostatin A results in increased degradation of TYMS protein	17172411
D014260	Triclosan	Triclosan results in increased expression of TYMS mRNA	29596926
D014260	Triclosan	Triclosan results in decreased expression of TYMS mRNA	30510588
D014271	Trifluridine	Trifluridine results in decreased activity of TYMS	19816940
C015559	trimellitic anhydride	trimellitic anhydride results in increased expression of TYMS mRNA	19042947
C016805	tris(1,3-dichloro-2-propyl)phosphate	tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of TYMS mRNA	26179874
D000077288	Troglitazone	Troglitazone results in decreased expression of TYMS mRNA	19140230
D014414	Tungsten	Tungsten results in increased expression of TYMS mRNA	30912803
C113580	U 0126	U 0126 inhibits the reaction [Cisplatin results in decreased degradation of TYMS protein]	21444628
C113580	U 0126	U 0126 results in decreased expression of TYMS mRNA	21444628
D014520	Urethane	Urethane results in decreased expression of TYMS mRNA	28818685
D014527	Uric Acid	NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of TYMS mRNA]	23619996
D014527	Uric Acid	Uric Acid results in decreased expression of TYMS mRNA	23619996
D014635	Valproic Acid	Valproic Acid results in decreased expression of TYMS mRNA	28001369
D014750	Vincristine	TYMS gene polymorphism affects the susceptibility to Vincristine	15713801
D014800	Vitallium	[Vitallium analog binds to titanium dioxide] which results in decreased expression of TYMS mRNA	23825117
D014800	Vitallium	Vitallium analog results in decreased expression of TYMS mRNA	23825117
D024483	Vitamin K 3	Vitamin K 3 affects the expression of TYMS mRNA	20044591
D000077337	Vorinostat	Vorinostat results in decreased expression of TYMS mRNA	20072153
D000077337	Vorinostat	Vorinostat results in decreased expression of TYMS protein	17172411
C085514	wogonin	[wogonin co-treated with Fluorouracil] results in increased expression of TYMS mRNA	20570612
C085514	wogonin	wogonin results in increased expression of TYMS mRNA	20570612
C094299	ZD 9331	ZD 9331 results in decreased activity of TYMS protein	15342418
D015215	Zidovudine	[Zidovudine co-treated with Lamivudine] results in decreased expression of TYMS mRNA	15784690
D015032	Zinc	Zinc deficiency results in increased expression of TYMS mRNA	22171008

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0025	Alternative splicing
KW-0963	Cytoplasm
KW-0903	Direct protein sequencing
KW-1017	Isopeptide bond
KW-0472	Membrane
KW-0489	Methyltransferase
KW-0496	Mitochondrion
KW-0999	Mitochondrion inner membrane
KW-0545	Nucleotide biosynthesis
KW-0539	Nucleus
KW-0597	Phosphoprotein
KW-1185	Reference proteome
KW-0808	Transferase
KW-0832	Ubl conjugation

Interpro

InterPro ID	InterPro Term
IPR023451	Thymidate_synth/dCMP_Mease
IPR036926	Thymidate_synth/dCMP_Mease_sf
IPR000398	Thymidylate_synthase
IPR020940	Thymidylate_synthase_AS

PROSITE

PROSITE ID	PROSITE Term
PS00091	THYMIDYLATE_SYNTHASE

Pfam

Pfam ID	Pfam Term
PF00303	Thymidylat_synt

Gene: TYMS

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Identified variants/mutations related to cleft phenotype

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction